ProThera Biologics is focused on the development of therapies for sepsis and anthrax intoxication. Its novel, proprietary technology is based on naturally occurring inhibitor proteins and is used to block the harmful anthrax toxin and prevent the severe inflammation (a potentially fatal complication also similar to that of sepsis) that follows. Sepsis is a severe condition characterized by an overwhelming systemic response to infection, which can rapidly lead to organ dysfunction and death. Each year, the nearly 800,000 newly diagnosed cases in the United States represent an annual healthcare cost of $17 billion.
ProThera is currently confirming the efficacy of its proteins for biodefense applications and conducting research on preventative strategies against brain damage in premature infants.
© 2013 Slater Technology Fund | Contact